ArticleThe Journal of infection2020
Interleukin-17: A potential therapeutic target in COVID-19.
Article in The Journal of infection, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Interleukins in COVID-19 and SARS-CoV-2 Variants: Immunopathogenesis, Therapeutic Perspectives and Vaccine-Induced Immune Responses.International journal of molecular sciences · 2026Review
- Article
- Evolutionary Insights from Sequence Analysis of Interleukin 17A (IL17A).Methods in molecular biology (Clifton, N.J.) · 2026Article
- Microbiome dysbiosis in SARS-CoV-2 infection: implication for pathophysiology and management strategies of COVID-19.Frontiers in cellular and infection microbiology · 2025Review
- Effects of Tocilizumab on Inflammation and Iron Metabolism in Critically Ill Patients with COVID-19.Pharmaceutics · 2023Article
- Biological sex and age-related differences shape the antiviral response to SARS-CoV-2 infection.Heliyon · 2023Article
- CanJournal of ginseng research · 2022Review
- The Role of Cytokines and Chemokines in Severe Acute Respiratory Syndrome Coronavirus 2 Infections.Frontiers in immunology · 2022Review
- Interleukin-17A influences the vulnerability rather than the size of established atherosclerotic plaques in apolipoprotein E-deficient mice.Open life sciences · 2022Article
- A novel hypothesis for COVID-19 pathogenesis: Retinol depletion and retinoid signaling disorder.Cellular signalling · 2021Article
- Article
- The signal pathways and treatment of cytokine storm in COVID-19.Signal transduction and targeted therapy · 2021Review
- Secukinumab in severe COVID-19 pneumonia: Does it have a clinical impact?The Journal of infection · 2021Article
- Impact of cytokine storm and systemic inflammation on liver impairment patients infected by SARS-CoV-2: Prospective therapeutic challenges.World journal of gastroenterology · 2021Review
- The impact of COVID-19 infection on the cytokine profile of pregnant women: A prospective case-control study.Cytokine · 2021Article
- Calming the inflammatory storm in severe COVID-19 infections: Role of biologics- A narrative review.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2021Review
- Antibody-Based Immunotherapeutic Strategies for COVID-19.Pathogens (Basel, Switzerland) · 2020Review
- REPLY TO: Interleukin-17: a potential therapeutic target in COVID-19.The Journal of infection · 2020Article
Corrections and comments
- Commented on by
- Comment on
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.